Nestlé develops nutritional and functional dairy products for GLP-1 users
Nestlé has started a global innovation strategy focused on formulating and marketing products for consumers using medicines such as Ozempic, Wegovy and Mounjaro, which are GLP-1 receptor agonists. The company is also targeting people receiving other medical therapies for weight control. The report was published in Mexico on August 18, 2026, by Forbes México.
The products are being designed around high-quality proteins, including whey protein and micellar casein. Nestlé is combining these dairy ingredients with prebiotic fibres, vitamins and essential minerals. The company’s stated focus is on foods with high nutritional density that can be offered in smaller portions.
The strategy is linked in the report to the appetite suppression associated with GLP-1 therapies. Patients receiving such treatments may face a higher risk of losing lean muscle mass and developing nutritional deficiencies. Nestlé’s formulations are therefore intended to provide protein and other nutrients within products adapted to those consumption patterns.
Commercially, the company is adapting its portfolio through specialised brands and its Nestlé Health Science division. The planned formats include ready-to-drink products, concentrated powders and nutritional supplements described as easy to digest. The initiative forms part of Nestlé’s response to changing food purchasing and consumption patterns among people using weight-management medicines.
The report also describes implications for dairy-ingredient suppliers and primary processing. Demand for protein isolates, concentrates and hydrolysates is increasing the value of specific milk fractions in the business-to-business market. Industrial plants are being encouraged to improve ultrafiltration and drying technologies to supply manufacturers of clinical and specialised nutrition products.
The development connects pharmaceutical treatments, medical nutrition and mass-market food production. Traditional categories such as confectionery, snacks and other calorie-dense products are identified as potentially affected by lower overall calorie intake among consumers. Nestlé’s initiative places high-specification dairy derivatives within the company’s broader wellness and preventive-nutrition business.
